BTG (LON:BTG) was downgraded by equities researchers at Deutsche Bank to a “hold” rating in a research note issued on Thursday. They presently have a GBX 645 ($8.75) target price on the stock, down from their previous target price of GBX 810 ($10.99). Deutsche Bank’s price objective would indicate a potential upside of 1.26% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Numis Securities reaffirmed a “buy” rating and issued a GBX 840 ($11.39) target price on shares of BTG in a report on Tuesday. Jefferies Group increased their price target on shares of BTG from GBX 775 ($10.51) to GBX 900 ($12.21) and gave the company a “buy” rating in a report on Tuesday. Shore Capital reissued a “buy” rating on shares of BTG in a report on Tuesday. Peel Hunt reissued a “hold” rating and issued a GBX 700 ($9.50) price target on shares of BTG in a report on Thursday, February 1st. Finally, JPMorgan Chase lowered their price target on shares of BTG from GBX 680 ($9.22) to GBX 650 ($8.82) and set a “neutral” rating on the stock in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of GBX 761.14 ($10.32).
Shares of BTG stock opened at GBX 637 ($8.64) on Thursday. BTG has a 52-week low of GBX 559.82 ($7.59) and a 52-week high of GBX 784 ($10.63).
BTG Company Profile
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.